Close

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

Leader
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Leader
Teri E. Klein, Ph.D.
Stanford University

Director
Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D.
Stanford University

Julie A. Johnson, Pharm.D.
University of Florida

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larissa Cavallari, Pharm.D.
University of Florida

Stuart Scott, Ph.D.
Icahn School of Medicine at Mount Sinai

Scientific Advisory Board

Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories

Robert Nussbaum, M.D.
University of California, San Francisco

Heidi Rehm, Ph.D.
Partners Healthcare

Marc S. Williams, M.D.
Geisinger

Sandy Aronson
Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D.
Northwestern University

  • Michelle Whirl-Carrillo -- Director of the PharmGKB! September 10, 2019
    We are happy to announce that Dr. Michelle Whirl-Carrillo has agreed to take on the position of Director of PharmGKB. Michelle has worked with the PharmGKB for over 15 years (not including a 1.5 year “sabbatical” at 23andme). She has served as lead curator, Assistant Director, and (since 2014) Associate Director. The PharmGKB grant has […]
  • CPIC to issue guidance on non-actionable pharmacogenes July 2, 2019
    The Clinical Pharmacogenetics Implementation Consortium (CPIC) hopes to provide more guidance in the future about gene-drug pairs which have a weak evidence base and are not clinically actionable, despite being heavily marketed to healthcare providers and the public. Many of these gene-drug pairs have already been curated by CPIC staff and assigned a CPIC level of C […]
  • PharmVar core alleles to be used by PharmGKB and CPIC May 21, 2019
    PharmVar has released core alleles - single, rule-based definitions per star allele distilled from the respective suballeles - for the cytochrome P450 genes CYP2C9, CYP2C19, and CYP2D6. Only sequence variations that change an amino acid or impact function by changing expression levels or interfere with splicing and are present in ALL suballeles within a star allele, […]
  • New CPIC Guideline: CYP2B6 and efavirenz May 1, 2019
    The CPIC Guideline for CYP2B6 and efavirenz is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for efavirenz, CYP2B6, and on the CPIC website.Efavirenz is a non-nucleoside reverse transcriptase inhibitor widely used worldwide to treat HIV-1 infection. It is predominantly metabolized into inactive metabolites by cytochrome P450-2B6 (CYP2B6). Genetic variants […]
  • CYP2C19 testing may assist with prescribing sertraline and escitalopram April 16, 2019
    Mary Relling (St. Jude Children's Research Hospital) and I (Teri Klein) as Co-Principal Investigators of the Clinical Pharmacogenetics Implementation Consortium (CPIC) have been discussing the letter that the FDA recently sent to a genomics laboratory expressing concern that “providers may make inappropriate treatment decisions based” on pharmacogenetic testing offered by that lab. The FDA specifically […]